Ironwood Pharma (IRWD) Misses Q4 EPS by 4c, Misses on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
February 27, 2025 7:00 AM ESTAnnounced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time
Initiated rolling NDA submission; on track to be completed in Q3 2025
LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year
2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million
BOSTON--(BUSINESS... More
